An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)

Gynecologic Oncology

Volumn 115, Issue 2, 2009, Pages 244-248

  Fader, Amanda Nickles ^a   Starks, David ^b   Gehrig, Paola A ^c   Secord, Angeles Alvarez ^d   Frasure, Heidi E ^b   O'Malley, David M ^e   Tuller, Erin R ^f   Rose, Peter G ^a   Havrilesky, Laura J ^d   Moore, Kathleen N ^f   Huh, Warner K ^g   Axtell, Allison E ^h   Kelley, Joseph L ⁱ   Zanotti, Kristine M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h OLIVE VIEW UCLA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Prognostic factors; Recurrence; Uterine papillary serous carcinoma

Indexed keywords

PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PARTIAL BODY RADIATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; RECURRENCE RISK; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TUMOR VOLUME; UTERUS CARCINOMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TAXOIDS; UTERINE NEOPLASMS;

EID: 70349737557     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.07.030     Document Type: Article

References (18)

1. Creasman W.T., Odicino F., et al. Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. J. Epidemiol. Biostat. 6 1 (2006) S141
2. Sagr E.R., Denschlaq D., Kerim-Dikeni A., et al. Prognostic factors and treatment related outcome in patients with uterine papillary serous carcinoma. Anticancer Res. 27 2 (2007) 1213-1217
3. Sherman M.E., Bitterman P., Rosenhein N.B., et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am. J. Surg. Pathol. 16 (1992) 600-610
4. Kato D.T., Ferry J.A., Goodman A., Sullinger J., Scully R.E., Goff B.A., et al. Uterine papillary serous carcinoma: a clinicopathologic study of 30 cases. Gynecol. Oncol. 59 3 (1995 Dec) 384-389
5. Fader A.N., Drake R.D., O'Malley D.M., Gibbons H.E., Huh W.K., Havrilesky L.J., et al. Platinum/taxane-based chemotherapy with or without radiotherapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115 6 (2009 May)
6. Fader A.N., Nagel C., Axtell A.E., Zanotti K.M., Kelley J.P., Moore K.N., et al. Stage II uterine papillary serous carcinoma: carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol. Oncol. 112 3 (2009) 558-562
7. Gynecologic Oncology Group Pathology Manual: Neoplasia of the Corpus, page IV2, 2009
8. Hendrickson M., Ross J., Eifel P., Martinez A., and Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial carcinoma. Am. J. Surg. Pathol. 6 2 (1982 Mar) 93-108
9. Goff B.A., Kato D., Schmidt R.A., Ek M., Ferry J.A., Muntz H.G., et al. Uterine papillary serous carcinoma: patterns of metstatic spread. Gynecol. Oncol. 54 3 (1994 Sep) 264-268
10. Sherman M.E., and Devesa S.S. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 98 1 (2003 Jul 1) 176-186
11. Santin A.D., Bellone S., Siegal E.R., et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am. J. Obstet. Gynecol. 192 3 (2005 Mar) 813-818
12. Wright J.D., Fiorelli J., Schiff P.B., et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer 115 6 (2009 Mar 15) 1276-1285
13. Slomovitz B.M., Broaddus R.R., and Burke T.W. Her2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. 22 (2004) 2136
14. Dietrich III C.S., Modesitt S.C., DePriest P.D., Ueland F.R., Wilder J., Reedy M.B., et al. The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 99 3 (2005) 557-563
15. Havrilesky L.J., Secord A.A., Bae-Jump V., Ayeni T., Calingaert B., Clarke-Pearson D.L., et al. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol. Oncol. 105 3 (2007) 677
16. Thomas M.B., Mariani A., Cliby W.A., Keeney G.A., Podratz K.C., and Dowdy S.C. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol. Oncol. 107 2 (2007) 186-189
17. Kelly M.G., O'Malley D.M., Hui P., McAlpine J., Yu H., Rutherford T.J., et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol. Oncol. 98 3 (2005 Sep) 353-359
18. Fields A.L., Einstein M.H., Novetsky A.P., Gebb J., and Goldberg G.L. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol. Oncol. 108 1 (2008) 201-206